PolTREG S.A.
@poltreg.com
PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.
PolTREG S.A.'s Company Logos
PolTREG S.A.'s Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#734DFF
Electric Violet
115, 77, 255
253, 100, 65
55, 70, 0, 0
#EFF4F3
Porcelain
239, 244, 243
168, 19, 95
2, 0, 0, 4
#0A3940
Tiber
10, 57, 64
188, 73, 15
84, 11, 0, 75
About PolTREG S.A.
PolTREG | Gdańsk is a leading biotechnology company founded in 2015 with headquarters and laboratories located in Gdańsk, Poland. The company's primary mission is to develop innovative T-regulatory cell (TREG) based therapies to effectively treat autoimmune diseases and improve the quality of life for patients and their families. PolTREG has made significant progress in this field, with four projects already in the clinical stage of development, focusing on type 1 diabetes and multiple sclerosis.
The company's portfolio also includes projects based on genetically modified T-regulatory lymphocytes. With a team of experienced managers, biotechnology specialists, and scientists, PolTREG is at the forefront of research and development in this field. They strive to become global leaders in providing platform therapies for autoimmune diseases.
In addition to their ongoing projects, PolTREG is actively expanding their product line to include CAR-TREGs and tissue-specific TREGs. Their ultimate goal is to partner with a prominent pharmaceutical company for the commercialization of their therapies. PolTREG is committed to revolutionizing the treatment of autoimmune diseases and continues to make groundbreaking contributions to the field of cell therapies
Company type
Public Company
Year founded
2015
Company size
51-200 employees
